Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.58 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CACNA1I | Q9P0X4 | 11/20 | 0.54 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770228 | 0.93 | KCNH2 (0.53) | KCNH2CACNA1HCYP2D6MAPTPOLB | |
| SCHEMBL4278216 | 0.91 | KCNH2 (0.64) | KCNH2CACNA1HCYP2D6MAPTPOLB | |
| SCHEMBL4282664 | 0.91 | CACNA1I (0.53) | KCNH2CACNA1HCYP2D6MAPTPOLB | |
| SCHEMBL19113052 | 0.90 | CYP2C9 (0.61) | KCNH2CYP2D6MAPTPOLBALDH1A1 | |
| SCHEMBL4273491 | 0.85 | MAPT (0.52) | KCNH2CACNA1HCYP2D6MAPTPOLB | |
| SCHEMBL4280568 | 0.85 | CACNA1I (0.50) | KCNH2CACNA1HCYP2D6MAPTPOLB | |
| SCHEMBL4276583 | 0.85 | KCNH2 (0.61) | KCNH2CACNA1HCYP2D6CACNA1IKMT2A | |
| SCHEMBL19113382 | 0.85 | MAPT (0.56) | KCNH2CACNA1HCYP2D6MAPTPOLB | |
| SCHEMBL4285578 | 0.84 | KCNH2 (0.78) | KCNH2CACNA1HCYP2D6CACNA1I | |
| SCHEMBL4278152 | 0.84 | KCNH2 (0.60) | KCNH2CACNA1HCYP2D6CACNA1IKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-01-09 | — | — | US | disclosed |
| US-8569344-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KCNH2 60/4885CACNA1H 2/4885CYP2D6 3619/4885 |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KCNH2 60/4885CACNA1H 2/4885CYP2D6 3619/4885 |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KCNH2 60/4885CACNA1H 2/4885CYP2D6 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.